SRZN Stock Analysis: Surrozen | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 195m USD | 12M Return: 186.6% | US86889P2083 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.38M
Qual. Beats: 0
Rev. Trend: -91.8%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 5.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Surrozen, Inc. (NASDAQ: SRZN) is a clinical-stage biotechnology company focused on discovering and developing antibody-based therapeutics that selectively modulate the Wnt signaling pathway to promote tissue repair. Founded in 2015 and headquartered in South San Francisco, California, the company went public in January 2021 and currently operates with a micro-cap market capitalization of approximately $267 million. Its research platform targets a broad range of disease areas, including conditions affecting the eye, retina, lung, liver, kidney, and central nervous system.
The companys lead programs are SZN-814, a bi-specific antibody combining Frizzled 4 (Fzd4) agonism with VEGF antagonism for retinal indications such as diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD); SZN-8143, which adds interleukin-6 (IL-6) antagonism to the same backbone; and SZN-413, a Fzd4-targeted bi-specific antibody for retinal vascular diseases. Surrozen has a collaboration and license agreement with Boehringer Ingelheim for Fzd4 bi-specific antibodies, and a research collaboration with TCGFB, Inc. focused on TGF-β-targeting therapeutics for idiopathic pulmonary fibrosis (IPF). As is typical for clinical-stage biotechs, the company has not yet commercialized a product and depends on partnerships and capital markets to fund its research and development activities.
- SZN-814 Phase 1 data readout in retinal disease patients
- Boehringer Ingelheim partnership milestone payments drive revenue upside
- Limited cash runway risks dilutive equity offering for pipeline development
| Net Income: -332.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -2.81 > 0.02 and ΔFCF/TA -269.6 > 1.0 |
| NWC/Revenue: 872.1% < 20% (prev 701.1%; Δ 171.0% < -1%) |
| CFO/TA -0.30 > 3% & CFO -34.8m > Net Income -332.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.1m) vs 12m ago 171.0% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 10.55% > 50% (prev 12.29%; Δ -1.74% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.87 (Total Current Assets 109.4m - Total Current Liabilities 9.01m) / Total Assets 115.6m |
| B: -5.23 (Retained Earnings -604.6m / Total Assets 115.6m) |
| C: -3.04 (EBIT TTM -332.2m / Avg Total Assets 109.2m) |
| D: -0.65 (Book Value of Equity -218.7m / Total Liabilities 334.3m) |
| Altman-Z'' = -32.49 = D |
| DSRI: 2.13 (Receivables 5.00m/2.57m, Revenue 11.5m/12.6m) |
| GMI: 0.93 (GM 88.57% / 95.33%) |
| AQI: 0.42 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.91 (Revenue 11.5m / 12.6m) |
| TATA: -2.57 (NI -332.1m - CFO -34.8m) / TA 115.6m) |
| Beneish M = -2.84 (Cap -4..+1) = A |
As of September 25, 2026, the stock is trading at USD 33.68 with a total of 11,526,993 shares traded. Over the past week, the price has changed by +98.82%, over one month by +40.51%, over three months by +36.08% and over the past year by +186.64%.
Current recommended Stop Loss: 31.90 (which is 5.3% or 1.3 ATR below the current price).
Surrozen has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy SRZN.
- StrongBuy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.8 | 33% |
P/S = 16.8987
P/B = 2.5049
Revenue TTM = 11.5m USD
EBIT TTM = -332.2m USD
EBITDA TTM = -332.0m USD
Long Term Debt = 4.33m USD (estimated: total debt 6.32m - short term 1.99m)
Short Term Debt = 1.99m USD (from shortTermDebt, last quarter)
Debt = 6.32m USD (from shortLongTermDebtTotal, last quarter) (leases 6.32m already included)
Net Debt = -95.7m USD (calculated: Debt 6.32m - CCE 102.0m)
Enterprise Value = 98.8m USD (194.5m + Debt 6.32m - CCE 102.0m)
Interest Coverage Ratio = unknown (Ebit TTM -332.2m / Interest Expense TTM 0.0)
EV/FCF = -0.30x (Enterprise Value 98.8m / FCF TTM -325.1m)
FCF Yield = -329.1% (FCF TTM -325.1m / Enterprise Value 98.8m)
FCF Margin = -2.82k% (FCF TTM -325.1m / Revenue TTM 11.5m)
Net Margin = -2.89k% (Net Income TTM -332.1m / Revenue TTM 11.5m)
Gross Margin = unknown ((Revenue TTM 11.5m - Cost of Revenue TTM 537k) / Revenue TTM)
Tobins Q-Ratio = 0.85 (Enterprise Value 98.8m / Total Assets 115.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.32m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -262.4m (EBIT -332.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.85 (Total Current Assets 109.4m / Total Current Liabilities 10.1m)
Debt / Equity = -0.03 (negative equity) (Debt 6.32m / totalStockholderEquity, last quarter -218.7m)
Debt / EBITDA = 0.29 (negative EBITDA) (Net Debt -95.7m / EBITDA -332.0m)
Debt / FCF = 0.29 (negative FCF - burning cash) (Net Debt -95.7m / FCF TTM -325.1m)
Total Stockholder Equity = -177.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -304.3% (out of range, set to none)
RoE = 187.6% (negative equity) (Net Income TTM -332.1m / Total Stockholder Equity -177.0m)
RoCE = 192.4% (negative capital employed) (EBIT -332.2m / Capital Employed (Equity -177.0m + L.T.Debt 4.33m))
RoIC = -243.0% (out of range, set to none) (NOPAT -262.4m / Invested Capital 108.0m)
WACC = 8.64% (E(194.5m)/V(200.8m) * Re(8.92%) + D(6.32m)/V(200.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 85.28 | Cagr: 191.6%
[DCF] Fair Price = unknown (Cash Flow -325.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: -91.76 | Revenue CAGR: -47.26% | SUE: 1.24 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-1.32 | Chg30d=+0.75% | Revisions=-40% | Analysts=3
EPS current Year (2026-12-31): EPS=-9.14 | Chg30d=+24.40% | Revisions=+0% | GrowthEPS=+0.0% | GrowthRev=+209.1%
EPS next Year (2027-12-31): EPS=-4.19 | Chg30d=+2.63% | Revisions=-40% | GrowthEPS=+54.2% | GrowthRev=-86.1%
[Analyst] Revisions Ratio: -57% (up=0, down=4)